Bleakley Financial Group LLC Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Bleakley Financial Group LLC bought a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 32,628 shares of the company’s stock, valued at approximately $81,000. Bleakley Financial Group LLC owned approximately 0.06% of Ventyx Biosciences as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Legal & General Group Plc boosted its position in Ventyx Biosciences by 152.3% in the second quarter. Legal & General Group Plc now owns 2,422 shares of the company’s stock valued at $30,000 after buying an additional 1,462 shares in the last quarter. UBS Group AG acquired a new position in Ventyx Biosciences in the fourth quarter valued at about $40,000. China Universal Asset Management Co. Ltd. boosted its position in Ventyx Biosciences by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,506 shares of the company’s stock valued at $52,000 after buying an additional 739 shares in the last quarter. SG Americas Securities LLC boosted its position in Ventyx Biosciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 37,261 shares of the company’s stock valued at $92,000 after buying an additional 14,177 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its position in Ventyx Biosciences by 93.7% in the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the company’s stock valued at $127,000 after buying an additional 1,870 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences Price Performance

VTYX opened at $4.76 on Wednesday. The company has a market cap of $335.58 million, a price-to-earnings ratio of -1.44 and a beta of 0.27. The firm has a 50 day simple moving average of $5.80 and a 200 day simple moving average of $6.71. Ventyx Biosciences, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.08. During the same quarter in the prior year, the company earned ($0.62) EPS. As a group, analysts expect that Ventyx Biosciences, Inc. will post -2.55 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Lifesci Capital upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. Wells Fargo & Company upgraded shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Oppenheimer upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Tuesday, March 12th. Finally, Canaccord Genuity Group reduced their target price on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.